Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515987 | 0.85 | NFE2L2 (0.48) | TRPA1CYP2D6 | |
| SCHEMBL10768077 | 0.82 | TRPA1 (0.55) | TRPA1LMNAKDM4E | |
| SCHEMBL10482798 | 0.78 | RELA (0.50) | TDP1LMNAKDM4E | |
| SCHEMBL1760765 | 0.76 | CYP1A2 (0.52) | TRPA1TDP1HTR2A | |
| SCHEMBL1760762 | 0.76 | CYP1A2 (0.52) | TRPA1TDP1HTR2A | |
| SCHEMBL315078 | 0.76 | HTR2A (0.41) | TDP1LMNAHTR2A | |
| SCHEMBL9325711 | 0.76 | TRPA1 (0.50) | TRPA1TAAR1ADRA2AADRA2CCYP2D6 | |
| SCHEMBL9747201 | 0.75 | TDP1 (0.36) | TAAR1TDP1ADRA2AADRA2CCYP2D6 | |
| SCHEMBL7366231 | 0.74 | ALDH1A1 (0.39) | TAAR1CYP2D6LMNAKDM4EHTR2A | |
| SCHEMBL21331657 | 0.74 | TRPA1 (0.50) | TRPA1TAAR1ADRA2AADRA2CCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | claimed |
| EP-0236138-B1 | DIHYDROPYRAN DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-08-07 | — | — | EP | claimed |
| US-4696964-A | HEAT RESISTANCE, OXIDATION RESISTANCE | CIBA-GEIGY CORPORATION (US) | 1987-09-29 | — | — | US | claimed |
| EP-0214102-A2 | 5-Aralkyl-substituted 2H-benzotriazoles and stabilized compositions | CIBA-GEIGY AG (CH) | 1987-03-11 | — | — | EP | claimed |
| EP-0125092-A1 | Bisbiguanide compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-11-14 | — | — | EP | claimed |
| US-4419490-A | GROUP 8 METAL | HEYL & CO. CHEMISCH-PHARMAZEUTISCHE FABRIK (DE) | 1983-12-06 | — | — | US | claimed |
| CN-108026241-B | Molded article and polymerizable composition for optical material | 三井化学株式会社 | 2021-11-19 | — | — | CN | disclosed |
| EP-2589643-B1 | HIGHLY EFFICIENT CARBAZOLE-BASED COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING SAME | SK CHEMICALS CO LTD (KR) | 2017-09-20 | — | — | EP | disclosed |
| US-9142784-B2 | Highly efficient carbazole-based compound, and organic electroluminescence device comprising same | SK CHEMICALS CO., LTD. (KR) | 2015-09-22 | — | — | US | disclosed |
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-20130119367-A1 | HIGHLY EFFICIENT CARBAZOLE-BASED COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING SAME | INDUSTRY ACADEMIC COOPERATION FOUNDATION, DANKOOK UNIVERSITY (KR) | 2013-05-16 | — | — | US | disclosed |
| EP-2589643-A2 | HIGHLY EFFICIENT CARBAZOLE-BASED COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING SAME | Industry-Academic Cooperation Foundation, Dankook University (KR) | 2013-05-08 | — | — | EP | disclosed |
| US-8420684-B2 | imidazole derivatives; Alzheimer's Disease, Down syndrome, Huntington's Disease; hypotensive agents; sleeping/eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 4-Cyclopropylimino-5-(3,4-dihydro-2H-pyran-2-yl)-1-(3-imidazol-1-yl-propyl)-imidazolidin-2-one | PROBIODRUG AG (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-0327409-A2 | Developer composition | THE MEAD CORPORATION (US) | 1989-08-09 | — | — | EP | disclosed |
| EP-0214935-A2 | Sterically hindered silicon ester stabilizers | CIBA-GEIGY AG (CH) | 1987-03-18 | — | — | EP | disclosed |
| EP-0214102-A2 | 5-Aralkyl-substituted 2H-benzotriazoles and stabilized compositions | CIBA-GEIGY AG (CH) | 1987-03-11 | — | — | EP | disclosed |
| US-4588771-A | Stabilized thiofunctional polysiloxane fluids and a process for stabilizing the same | SWS SILICONES CORPORATION (US) | 1986-05-13 | — | — | US | disclosed |
| US-4490487-A | SO3 /Imide adducts, process for their preparation and their use as sulphonating agents | BAYER AKTIENGESELLSCHAFT (DE) | 1984-12-25 | — | — | US | disclosed |
| EP-0086917-A1 | Heterocyclic compounds useful as pesticides and processes for making them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-08-31 | — | — | EP | disclosed |
| US-4191829-A | LIGHT STABILIZERS | CIBA-GEIGY CORPORATION (US) | 1980-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130119367-A1 | HIGHLY EFFICIENT CARBAZOLE-BASED COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING SAME | PPIP5K2, INPP5B, EZH2 | TRPA1 1221/4885TAAR1 4528/4885TDP1 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.